University of Virginia School of Law professor George Rutherglen is providing pro bono legal representation to a seriously ill prisoner in a lawsuit that highlights the challenges of treating inmates for hepatitis C.
The lawsuit accuses Virginia Department of Corrections employees of denying potentially life-saving treatments to Elmo Augustus Reid, a 60-year-old inmate at the Buckingham Correctional Center.
The defendants are Mark Amonette, chief physician of the department; Bernard W. Booker, warden of the correctional center; and Pamela Shipp, health authority for the center.
A renowned hepatitis expert said Hong Kong could be among the first cities in the world to eradicate hepatitis C, if a citywide action plan is formulated.
Professor Henry Chan Lik-yuen, chairman of a hepatitis advisory committee under the World Health Organisation, said insufficient data and the absence of a comprehensive policy were both significant barriers to effective treatment of the liver disease. But Hong Kong could take the lead in bringing the number of cases down to zero if the issues were remedied, he said.
“If we could set a timetable to treat a certain number of cases by a certain time, patients would not have to wait ages for treatment,” Chan said.
A new cure for hepatitis C in children and adolescents is on the way, promising to help some of the silent victims of a nationwide heroin epidemic.
A Cincinnati Children’s Hospital Medical Center doctor who helped lead the research for the drug combination says the new medication regiment brings hope for all children with the disease.
“Years ago, I told my patients’ parents that, in your child’s lifetime, we’re going to have a cure for this,” said Dr. William Balistreri, lead author of the study and medical director emeritus for Cincinnati Children’s Pediatric Liver Care Center. Before this, he said, “there wasn’t anything that was really reliable.”
Prime Therapeutics recently announced that 97% of hepatitis C patients who were treated with Gilead’s Harvoni (ledipasvir/sofosbuvir) were cured of the virus in a new real-world study. The results obtained are similar to those previously found in clinical trials, which ranged from 94% to 99%.
Prime, a pharmacy benefit manager (PBM), will present the study data at the Academy of Managed Care Pharmacy’s 2017 Annual Meeting (AMCP 2017) March 27-30 in Denver, Colorado.
Harvoni is a prescription medicine used with or without ribavirin to treat chronic hepatitis C virus (HCV) infection with the viral genotypes 1, 4, 5 or 6.
Four years ago, the first curative pills for hepatitis C virus (HCV) were handed to patients. These drugs were a breakthrough for people infected with this pathogen. Lacking in serious side effects and eradicating the virus from the body in just 12 weeks, these so-called direct-acting antivirals (DAAs) offered a clean escape from this potentially fatal liver illness.
But with numerous DAAs now available—along with their long trail of clinical trial data—primary care physicians are left to navigate a crowded and confusing landscape for treating HCV. Controversy surrounding the cost of these drugs has also become a concern.
As a result, doctors may be hesitant to treat patients directly, preferring instead to refer them to liver specialists or delay treatment until symptoms arise, which could be several years after the infection is diagnosed. “Many primary care physicians are still too unfamiliar with the regimens to speak with confidence about them,” says hepatologist Ira Jacobson, who leads the department of medicine at Mount Sinai Beth Israel Hospital in New York.
IOWA CITY, Iowa (KCRG-TV9) – The Iowa State Registry announced its annual report Wednesday morning. It shows cancer is on the rise in the state. It projects more than 17,000 cases in 2017, that’s 800 more than last year.
Liver cancer was a major topic at the University of Iowa College of Public Health. Survivor Bill Klahn shared the story of his fight. He was diagnosed with Hepatitis C at a routine physical.
“When my blood work came back they told me that I was dying. I said, ‘what I’m working 60-70 hours a week, I’m going to the gym working out, there’s no way,’” Klhan said.
March is Fatty Liver Month. Fatty liver will replace hepatitis C as the leading cause of liver transplants and deaths related to liver disease in the near future. As fatty liver relates to hepatitis C learn about the connection between HCV genotype 3, and fatty liver, click here.